Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Other financing activities (2021 - 2025)

Historic Other financing activities for TScan Therapeutics (TCRX) over the last 3 years, with Q2 2025 value amounting to $75000.0.

  • TScan Therapeutics' Other financing activities changed N/A to $75000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $294000.0, marking a year-over-year change of. This contributed to the annual value of $324000.0 for FY2022, which is N/A changed from last year.
  • Per TScan Therapeutics' latest filing, its Other financing activities stood at $75000.0 for Q2 2025.
  • In the past 5 years, TScan Therapeutics' Other financing activities ranged from a high of $748000.0 in Q2 2021 and a low of -$960000.0 during Q3 2021
  • For the 3-year period, TScan Therapeutics' Other financing activities averaged around $74857.1, with its median value being $125000.0 (2025).
  • Over the last 5 years, TScan Therapeutics' Other financing activities had its largest YoY gain of 12395.83% in 2022, and its largest YoY loss of 12395.83% in 2022.
  • Quarter analysis of 3 years shows TScan Therapeutics' Other financing activities stood at -$960000.0 in 2021, then soared by 109.79% to $94000.0 in 2022, then fell by 20.21% to $75000.0 in 2025.
  • Its last three reported values are $75000.0 in Q2 2025, $125000.0 for Q1 2025, and $94000.0 during Q4 2022.